May 12 2011 11:04 AMHPLC, UHPLC, LC-MS

Liquid Chromatography development for determination of ebastine in pharma

 
Scientists have developed a new method for determining ebastine in its pharmaceutical preparations, according to 7th Space Interactive.

The news source reported that this model depends on the complexation ability of the studied drug with Zn2+ ions.
Reversed phase chromatography was carried out using an ODS c18 stainless steel column with UV-detection at 260nm.

Furthermore, a mobile phase containing 0.025 per cent w/v Zn2+ in a mixture of (acetonitril/methanol) and Britton Robinson buffer, which was adjusted to a pH of 4.2, was used to determine the ebastine at a flow rate of one ml/min.

It was also reported that content uniformity testing of the method was also conducted, while the make-up of the complex and its stability constant was looked into.

Recently, liquid chromatography was used to analyse endometrial hyperplasia and carcinoma, with findings published in the Journal of Hematology and Oncology, highlighting that these gynaecological malignancies are the most common.ADNFCR-3194-ID-800529413-ADNFCR

Request more information

You are requesting more details on: Liquid Chromatography development for determination of ebastine in pharma.

Your details will be referred to Breaking News and they will provide you with more information regarding this press release themselves. If you have not logged into the website, then please enter your details below.

Contact Details:

* Required fields

top of page Filed under: HPLC, UHPLC, LC-MS

Reader Comments (Total 0 comments)

Post a comment

Do you like or dislike what you have read? Why not post a comment to tell others / the manufacturer and our Editor what you think. To leave comments please complete the form below. Providing the content is approved, your comment will be on screen in less than 24 hours. Leaving comments on product information and articles can assist with future editorial and article content. Post questions, thoughts or simply whether you like the content.

Post your comment:

top of page